HIV Curbside

HIV Prevention: PrEP and Patient Adherence – Pearls for Success: Screening and Risk Assessment

Author(s)/Faculty: Raphael J. Landovitz, MD, MSc; Meredith E. Clement, MD
Release Date: 4/12/2022Expiration Date: 4/11/2023
Credit Type: CME / CPENumber of Credits: 0.5
Content Type: VideoProvider:
HIV is a disease that attacks the body’s immune system. Patients with HIV have the capability to transmit the virus to other patients via either sex or sharing of needles or syringes. If HIV is not treated, it can lead to AIDS, which is the most severe phase of HIV infection. Because there is no effective vaccine to prevent HIV transmission, behavioral and biomedical HIV-prevention strategies are needed to reduce HIV acquisition. For HIV-uninfected patients, pre-exposure prophylaxis (PrEP) using antiretroviral medications is an evidence-based method to prevent new infections among those at greatest risk, as data have shown that PrEP is highly effective in individuals who are adherent to taking the agent. In this Curbside Consult, Meredith E. Clement, MD, and Raphael J. Landovitz, MD, MSc, discuss a case of a cisgender woman seeking screening and risk assessment for HIV as well as considering whether she would benefit from PrEP.